Trial summary
This is a secondary data use non-interventional study of patients in Australia who received Sacituzumab govitecan (Trodelvy), for the treatment of unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.
Trial details
Short title
TRACIE / CO-AU-979-6695
Diagnosis
Breast cancer
Type of treatment
Medical Oncology
Phase
Registry
Locations
Who can participate
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your healthcare provider if you are interested in this clinical trial.